A Fulbright Scholar, Mr. Antikarov has held leadership roles in sophisticated financial transactions, corporate finance, strategy development, and enterprise risk management, driving gains in revenue, profitability, and shareholder value. Currently, he is a CFO of Epione Pharmaceuticals. His experience includes work with Fortune 500 companies, as well as international front runners such as AT&T, Merck, Lockheed Martin, Alcatel-Lucent, Thomson Reuters, Philips, OSG, Roche, Valle, Votorantim, Telefonica and Axel Johnson. He is co-author of a best-selling book, Real Options, A Practitioner’s Guide, which is used by MIT, Harvard and The Wharton School and by corporate finance practitioners. Antikarov is cited as a thought partner in McKinsey & Company’s book Valuation: Measuring and Managing the Value of Companies.